Attached files
file | filename |
---|---|
EX-99.3 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex993.htm |
EX-99.1 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex991.htm |
EX-5.1 - OPINION ON LEGALITY - Sanara MedTech Inc. | smti_ex51.htm |
EX-1.1 - UNDERWRITING AGREEMENT - Sanara MedTech Inc. | smti_ex11.htm |
8-K - CURRENT REPORT - Sanara MedTech Inc. | smti_8k.htm |
Exhibit 99.2
Sanara MedTech Inc. Announces Pricing of Public
Offering
FORT WORTH, TX / ACCESSWIRE / February 12, 2021 / Sanara
MedTech Inc.
Based in Fort Worth, Texas, Sanara MedTech Inc.
(“Sanara,” the “Company,” “we,”
“our” or “us”) (NASDAQ: SMTI), a provider
of wound and skin care products dedicated to improving patient
outcomes, today announced the pricing of its underwritten public
offering of 1,100,000 shares of common stock at a public offering
price of $25.00 per share. In addition, Sanara has granted the
underwriters a 30-day option to purchase up to an additional
165,000 shares of common stock. Sanara anticipates the total gross
proceeds from the offering (before deducting the underwriting
discounts and offering expenses) will be $27.5 million, excluding
any exercise of the underwriters' option to purchase additional
shares. The offering is expected to close on February 17, 2021,
subject to customary closing conditions.
Cantor Fitzgerald & Co. is acting as the sole book-running
manager for the offering.
The shares of common stock are being offered by the Company
pursuant to a registration statement previously filed with and
declared effective by the Securities and Exchange Commission (the
"SEC"). The offering will be made only by means of a prospectus,
consisting of a prospectus supplement and an accompanying
prospectus. A final prospectus supplement and an accompanying
prospectus relating to the offering will be filed with the SEC and
will be available on the SEC's website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus, when filed with the SEC, may also be
obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 6th
Floor, New York, NY 10022, Attn: Capital Markets Department, or by
email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based
healing solutions and services, Sanara MedTech Inc. markets and
distributes wound and skin care products and is seeking to offer
wound care and dermatology virtual consultation services via
telemedicine to physicians, hospitals, clinics, and all post-acute
care settings. Sanara’s products are primarily sold in the
North American advanced wound care and surgical tissue repair
markets. Sanara MedTech markets and distributes CellerateRX®
Surgical Activated Collagen® to the surgical markets as well
as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser,
BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™
Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™
Hydrolyzed Collagen Powder and Gel. We are constantly seeking
long-term strategic partnerships with a focus on products and
technologies that improve outcomes at a lower overall cost. In
addition, Sanara is actively seeking to expand within its six focus
areas of wound and skin care for the acute, post-acute, and
surgical markets. The focus areas are debridement, biofilm removal,
hydrolyzed collagen, advanced biologics, negative pressure wound
therapy adjunct products, and the oxygen delivery system segment of
the healthcare industry.
Forward-Looking Statements
The statements in this press release that do not constitute
historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “may,”
“will,” “would,” “should,”
“expect,” “plan,” “anticipate,”
“could,” “intend,” “target,”
“project,” “contemplates,”
“believes,” “estimates,”
“predicts,” “preliminary,”
“potential” or “continue” or the negatives
of these terms, variations of these terms or other similar
expressions. These forward-looking statements include statements
regarding the expected timing of the closing of the offering, the
development of new products and expansion of the Company’s
business in telehealth and wound care. These items involve risks,
contingencies and uncertainties such as risks and uncertainties
associated with market conditions and the satisfaction of customary
closing conditions related to the offering, the extent of product
demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and
integrate acquisitions, and other risks, contingencies and
uncertainties detailed in the Company’s SEC filings, which
could cause the Company’s actual operating results,
performance or business plans or prospects to differ materially
from those expressed in, or implied by these
statements.
All forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to revise
any of these statements to reflect the future circumstances or the
occurrence of unanticipated events, except as required by
applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.